PKC theta inhibitors (Evommune/Axcelead Drug Discovery)

N/A

Report date: 2025/03/20 09:23:12
NME

Base Information

Drug NamePKC theta inhibitors (Evommune/Axcelead Drug Discovery)
Drug Alias Nameprotein kinase C theta inhibitors (Evommune/Axcelead Drug Discovery)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C theta inhibitors
TargetsProtein kinase C theta
Therapy Area/IndicationsPsoriasisDermatitis, AtopicAsthma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAxcelead Drug Discovery Partners Inc
China Registration ClassN/A

Develop Information

Active CompaniesAxcelead Drug Discovery Partners IncEvommune Inc
Inactive CompaniesN/A
Active IndicationsPsoriasisDermatitis, AtopicAsthma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A